State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar.
Kwon Y, Sarpatwari A, Dusetzina SB.
europepmc +1 more source
A comparison of JC virus assay performance provided with originator and biosimilar natalizumab. [PDF]
Varley J+7 more
europepmc +1 more source
Evaluation of Methods Employed in Establishing Preclinical Similarity of Adalimumab Biosimilars. [PDF]
Nair R+3 more
europepmc +1 more source
Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation.
Murphy SJ, Holtkamp NC.
europepmc +1 more source
A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (Perjeta<sup>®</sup>) in healthy male subjects. [PDF]
Li Y, Wang Y, Yang C, Zhao N, Wang X.
europepmc +1 more source
In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20. [PDF]
Bray JS+6 more
europepmc +1 more source
Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan. [PDF]
Chang TW+4 more
europepmc +1 more source
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome. [PDF]
Jang JH+4 more
europepmc +1 more source
Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn's Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials. [PDF]
Strand V.
europepmc +1 more source